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An artificial operon was synthesized, consisting of
the genes for chorismate pyruvate-lyase of E. coli
and for 4-hydroxybenzoate 3-hydroxylase ofCoryne-
bacterium cyclohexanicum. This operon, directing
the biosynthesis of 3,4-dihdroxybenzoate, was ex-
pressed in the heterologous expression hostStrepto-
myces coelicolor M512, together with a modified
biosynthetic gene cluster for the aminocoumarin anti-
biotic clorobiocin. The resulting strain produced
a clorobiocin derivative containing a 3,4-dihdroxy-
benzoyl moiety. Its structure was confirmed by MS
and NMR analysis, and it was found to be a potent
inhibitor of the gyrases from Escherichia coli and
Staphylococcus aureus. Bioassays against different
E. coli mutants suggested that this compound is
actively imported by catechol siderophore trans-
porters in the cell envelope. This study provides an
example of the structure of a natural product that
can be rationally modified by synthetic biology.
INTRODUCTION
The first experiment showing that a new antibiotic can be
produced by genetic engineering, i.e., by the combination of
biosynthetic genes from different organisms, was published in
1985 (Hopwood et al., 1985). Since then, the number of biosyn-
thetic genes and gene clusters available for such experiments,
and the genetic techniques available for recombination and
expression have expanded greatly, and many new bioactive
compoundshavebeengeneratedbygeneticengineeringofmicro-
organisms (Hopwood, 2009a, 2009b). Advances in the methods
of chemical DNA synthesis now allow to readily adapt the codon
usage in a given gene to the codon usage of different expression
hosts. This greatly expands the possibilities for the generation
of new bioactive compounds by the combination of genes from
very different organisms in a suitable host strain using a synthetic
biology approach. The present paper reports the rational design
of a structurally modified antibiotic by such a strategy.304 Chemistry & Biology 18, 304–313, March 25, 2011 ª2011 ElsevieThe aminocoumarin antibiotics are characterized by their
3-amino-4,7-dihydroxycoumarin moiety (Heide, 2009a). This
family of antibiotics comprises potent DNA gyrase inhibitors,
including clorobiocin and the structurally related novobiocin (Fig-
ure 1). These compounds interact with the subunit B of bacterial
DNA gyrase and inhibit ATP-dependent supercoiling of DNA,
which is essential for transcription and DNA replication in
bacteria. The therapeutic potential of the aminocoumarins lies
especially in their very high affinity to gyrase. Their equilibrium
dissociation constants (KD) for gyrase is in the 10 nM range,
i.e., much lower than that of modern fluoroquinolones (Maxwell
and Lawson, 2003). Even though clorobiocin is a more potent
inhibitor of DNA gyrase, only novobiocin (Albamycin) has been
licensed for clinical use in human infections with Gram-positive
bacteria such as methicillin-resistant Staphylococcus aureus
strains (Maxwell and Lawson, 2003). However, due to its poor
solubility in water and its low activity against Gram-negative
pathogens, clinical application of novobiocin remains restricted.
Over the last years, the biosynthetic gene clusters of five
different aminocoumarin antibiotics have been cloned and
sequenced (Heide, 2009a), and this group of antibiotics has
become a successful example for the generation of new anti-
biotics by genetic techniques, e.g., metabolic engineering,
mutasynthesis, and chemoenzymatic synthesis (Heide, 2009b).
Structurally, clorobiocin is composed of three moieties: the
acylated noviose deoxysugar (Ring C), the 3-amino-4,7-dihy-
droxycoumarin which is chlorinated at 80-position (Ring B), and
the 3-dimethylallyl-4-hydroxybenzoyl moiety (Ring A). These
threemoieties are linked by a glycosidic and an amide bond (Fig-
ure 1). X-ray crystallographic studies have shown that RingB and
Ring C are essential for the interactions of clorobiocin (as well as
novobiocin) with gyrase, while Ring A ismuch less involved in the
bindingof theantibiotic to the target (Maxwell andLawson, 2003).
Therefore, it appears possible to vary the structure of Ring A
without severely affecting the DNA gyrase inhibitory activity.
A principal shortcoming of the aminocoumarin antibiotics is
their poor activity against Gram-negative organisms which is
partly due to their poor permeation across the outer membrane
of these organisms (Tropp et al., 1995). Gram-negative bacteria
have efficient iron acquisition systems which consist of outer
membrane proteins that bind iron complexes of specific sidero-
phores and facilitate their active transport into the cell (Neilands,
1995). Many siderophores, like enterobactin of Escherichia coli,r Ltd All rights reserved
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Figure 2. Substrate Tolerance of Different Aminocoumarin Acyl
Ligases
Activity of different aminocoumarin acyl ligases with acyl substrates containing
catechol motifs. Amide bond formation was determined with 3-amino-4,7-
dihydroxy-8-methyl-coumarin as amino substrate in the presence of ATP
and Mg2+, as described in the Experimental Procedures.
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Artificial Pathway to a New Coumarin Antibioticcontain catechol (= o-diphenol) motifs. Their hydroxyl groups are
responsible for chelating theFe3+ ion (Neilands, 1995). Thebacte-
rial iron uptake mechanisms offers a possibility to overcome
membrane-associated drug resistance by a Trojan horse
approach (Miethke and Marahiel, 2007; Mo¨llmann et al., 2009).
It hasbeenshownthatbeta-lactamantibiotics towhichacatechol
moiety had been chemically attached were transported by side-
rophore transporters into the Gram-negative cell, resulting in an
enhanced antibacterial activity (Mo¨llmann et al., 2009). In the
present study, we attempted to develop a clorobiocin derivative
with a catechol moiety instead of the genuine Ring A, using
a synthetic biology approach, and to test whether it would be
transported into the cell under involvement of catechol sidero-
phore transporters. We (1) isolated the gene cluster for clorobio-
cin from a Streptomyces strain; (2) deleted the pathway to the
genuine Ring A moiety of this antibiotic from the cluster by gene
inactivation; (3) constructed a new, artificial biosynthetic pathway
to a catechol moiety by combining one gene from the Gram-
negative Escherichia coli and one gene from the Gram-positive
Corynebacterium cyclohexanicum into a synthetic operon; (4) ex-
pressed these genes from three different organisms in a fourth
organism, i.e., Streptomyces coelicolor M512, as heterologous
host. This genetic strategy resulted in the production of the
desired compound, i.e., a clorobiocin derivative with a catechol
(= o-diphenol) moiety. We could provide evidence that this
compound was transported across the cell envelope of E. coli
under involvement of TonB-dependent transporters, i.e., bacte-
rial siderophore transporters which recognize catechol moieties.
RESULTS
Investigation of the Substrate Tolerance of Different
Aminocoumarin Acyl Ligases for Acyl Substrates
with Catechol Moieties
The aim of our study was the replacement of the genuine 3-di-
methylallyl-4-hydroxybenzoyl moiety (= Ring A) in clorobiocinChemistry & Biology 18, 3(Figure 1) with an acyl moiety containing a catechol structure.
We considered six different acids which contain catechol motifs
(Figure 2). Previous mutasynthetic experiments, aimed at the
replacement of Ring A by other acyl groups, had shown that
the success of those experiments is dependent primarily on
the acceptance of the acyl substrate by the aminocoumarin
acyl ligase (= amide synthetase) which attaches the acyl moiety
to the 3-amino group of the aminocoumarin moiety (Anderle
et al., 2007; Galm et al., 2004a). The later biosynthetic steps,
i.e., glycosylation and final tailoring steps, appeared not to be
affected by modifications of the structure of the acyl moiety.
We therefore tested the acceptance of the six acyl substrates
with catechol motifs (Figure 2) by four different aminocoumarin
acyl ligases, i.e., NovL, CloL, CouL, and SimL, obtained from
the biosynthetic gene cluster of novobiocin, clorobiocin, cou-
mermycin A1, and simocyclinone D8, respectively. These four
enzymes were expressed and purified as described previously
(Galm et al., 2004a; Luft et al., 2005; Schmutz et al., 2003;
Steffensky et al., 2000a). Aminocoumarin acyl ligase activity
was tested using 3-amino-4,7-dihydroxy-8-methyl-coumarin
as amino substrate and the six catechols as acyl substrates in
an in vitro assay for amide formation (see Experimental Proce-
dures). The identity of the resulting compounds was confirmed
by LC-MS. As shown in Figure 2, the best accepted catechol
substrate was 3,4-dihydroxybenzoic acid (3,4-DHBA). In case04–313, March 25, 2011 ª2011 Elsevier Ltd All rights reserved 305
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Artificial Pathway to a New Coumarin Antibioticof CloL, amide bond formation with this substrate reached 42%
of the reaction velocity observed with the genuine substrate Ring
A. Caffeic acid was not accepted by CloL but by SimL, albeit only
to a low extent. The other four catechols were not accepted by
any of the investigated enzymes. We therefore concentrated
further experiments on 3,4-DHBA and the aminocoumarin acyl
ligase of clorobiocin biosynthesis, i.e., CloL.
Inactivation of cloQ in the Biosynthetic Gene Cluster
of Clorobiocin, and Heterologous Expression
of the Modified Cluster
In order to replace Ring A in clorobiocin with 3,4-DHBA, the
biosynthesis of Ring A had to be abolished to avoid competition
between the genuine and the artificial acyl moiety as precursor in
the antibiotic biosynthesis. The first committed step in Ring A
biosynthesis is the prenylation of 4-hydroxyphenylpyruvate
under catalysis of CloQ (Pojer et al., 2003). Therefore, we carried
out an inactivation of the gene cloQ within the biosynthetic gene
cluster of clorobiocin.
The heterologous expression cosmid clo-BG1, containing the
clorobiocin biosynthetic gene cluster, had been prepared previ-
ously (Eusta´quio et al., 2005). It contains the FC31 attachment
site for stable integration into the genome of different Strepto-
myces host strains. Using Red/ET-mediated recombination,
we replaced the coding sequence of cloQ with an apramycin
resistance gene (see Experimental Procedures). The resistance
cassette was subsequently removed by restriction digestion
and religation, using XbaI and SpeI sites introduced into the
PCR primer sequence as described previously (Gust, 2009).
This cloQ-deficient gene cluster was integrated into the genome
of S. coelicolor M512, resulting in S. coelicolor M512(clo-SA2).
Cultivation of this strain in clorobiocin production medium did
not result in production of clorobiocin, while corresponding
heterologous expression strains containing the intact cluster
produce this antibiotic (Eusta´quio et al., 2005; Flinspach et al.,
2010). However, feeding of Ring A (1 mg per 80 ml culture
medium) restored production of clorobiocin, as confirmed by
HPLC and HPLC-MS analysis in comparison to an authentic
reference compound. Therefore, the inactivation of cloQ had
led to the abolishment of the production of Ring A, but had not
affected the subsequent steps of clorobiocin biosynthesis.
Mutasynthetic Experiments with 3,4-DHBA
and Caffeic Acid
Feeding of different amounts of 3,4-DHBA to cultures of S. coeli-
colorM512(clo-SA2) did not lead to the formation of a clorobiocin
derivative, as shown in HPLC and LC-MS analysis. In a parallel
experiment, we also fed caffeic acid. In these experiments,
we additionally introduced a SimL expression plasmid, pSH2
(Anderle et al., 2007), since SimL but not CloL was able to accept
caffeic acid (Figure 2). Also these experiments remained unsuc-
cessful. However, we noticed that caffeic acid was clearly de-
tected in the cultures after feeding, while no detectable amounts
of 3,4-DHBA were present in the cultures already one day after
feeding. We speculated that 3,4-DHBA may rapidly be oxidized
in the medium, or may quickly be metabolized by catabolic path-
ways similar to those described in Corynebacterium (Merkens
et al., 2005). We therefore considered whether a continuous
in vivo biosynthesis of 3,4-DHBAmight be superior to an external306 Chemistry & Biology 18, 304–313, March 25, 2011 ª2011 Elseviefeeding of this compound in order to supply 3,4-DHBA for ami-
nocoumarin antibiotic formation.
Creating an Artificial Pathway to 3,4-Dihydroxybenzoic
Acid
3,4-DHBA can be formed by the well-characterized 4-hydroxy-
benzoate-3-hydroxylase PobA ofCorynebacterium cyclohexani-
cum (Figure 3) (Fujii and Kaneda, 1985; Huang et al., 2008). This
44 kDa flavoprotein monooxygenase is involved in catabolic
processes, e.g., lignin degradation. In all Gram-positive bacteria
it uses NADH in order to provide the required reduction equiva-
lents. However, the substrate of PobA, 4-hydroxybenzoic acid
(4HBA), is not expected to be present in Streptomyces in high
concentrations. 4HBA is an intermediate of ubiquinone biosyn-
thesis. In most organisms, it is formed by degradation of tyrosine
(Meganathan, 2001). However, Gram-negative bacteria such as
E. coli derive 4HBA directly from chorismate by elimination of the
enol-pyruvyl side chain under catalysis of chorismate pyruvate
lyase, a 19 kDa protein encoded by the gene ubiC (Figure 3)
(Siebert et al., 1992). The reaction does not require cofactors.
By heterologous expression of ubiC in the chloroplasts of plants,
which do not contain an ortholog of this gene, very large amounts
of 4HBA could be generated without any detrimental effect on
growth (Viitanen et al., 2004). Also Streptomyces genomes do
not contain an ortholog of ubiC. An expression of both ubiC
and pobA therefore presented an attractive possibility to
generate 3,4-DHBA in our Streptomyces strains in vivo.
The GC content of ubiC of E. coli is 53%, much lower than the
average content in genes of the GC-rich Streptomyces. There-
fore, the sequence of ubiC was modified in order to adapt it to
the codon preference of Streptomyces. The Gene Designer
program (DNA 2.0, Menlo Park, CA) was employed for this
purpose, using the codon usage table of Streptomyces coeli-
color. The same was done for the gene pobA of Corynebacte-
rium cyclohexanicum, although fewer modifications were
required for this gene from a GC-rich species. The two genes
were translationally coupled in order to increase translation effi-
ciency and to facilitate co-regulation. The nucleotide sequence
of the synthetic ubiC/pobA construct is given in Figure S1 (avail-
able online). After commercial synthesis, this DNA fragment
was cloned into the Streptomyces expression vector pUWL201
(Doumith et al., 2000), placing it under control of the strong
constitutive ermE* promoter. The resulting plasmid, pSA11,
was introduced into S. coelicolor(clo-SA2) by protoplast trans-
formation. Thereby, all genes required for the biosynthesis of
the desired compound were assembled in the heterologous
expression strain (Figure 3).
Production of Novclobiocin 401 by Streptomyces
coelicolor(clo-SA2) Harboring Plasmid pSA11
Strain S. coelicolor(clo-SA2) harbouring pSA11 was cultivated in
three different media: (1) the complex clorobiocin production
medium described for the wild-type producer strain Strepto-
myces roseochromogenes var. oscitans DS 12.976 (Mancy
et al., 1974); (2) the complexGYMmediumdescribed forS. coeli-
color A3(2) fermentation (Shima et al., 1996); (3) the chemically
defined medium (CDM) developed for novobiocin production in
the wild-type producer strain Streptomyces niveus (Kominek,
1972). Ethyl acetate extracts from cultures in the three mediar Ltd All rights reserved
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Figure 3. Strategy for the Generation of a Clorobiocin Derivative Containing a 3,4-Dihydroxybenzoyl Moiety
The sequence of the synthetic ubiC/pobA operon is shown in Figure S1.
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Artificial Pathway to a New Coumarin Antibioticwere analyzed by HPLC and LC-MS. The formation of a new
compound with the expected molecular ion of m/z 643 [M-H]-
was detected in all media. The amount of this compound was
moderate using the two complex media (4 and 7 mg/ml, respec-
tively), but was much higher using the chemically definedculture extract
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Figure 4. HPLC and LC-MS Analysis
(A) HPLC chromatogram of a culture extract from the heterologous producer stra
(B) Purified compound isolated from cultures in CDM medium.
(C) Mass spectrometric fragmentation of novclobiocin 401 obtained by selected
negative mode for m/z 643. The suggested fragmentation scheme for the compo
Chemistry & Biology 18, 3medium (64 mg/ml). In this case, the new metabolite clearly rep-
resented a major compound in the extract (Figure 4A). Prepara-
tive isolation of this metabolite from 2 l of culture resulted in
18mg of pure compound (Figure 4B). This new clorobiocin deriv-
ative was termed novclobiocin 401.mass spectrometric fragmentation of 
novclobiocin 401
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Figure 5. Determination of the Inhibitory Activity by Supercoiling
and Decatenation Assays
Supercoiling (A) and decatenation (B) assays with E. coli and S. aureus DNA
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LC-MS analysis in negative mode showed the presence of the
molecular ion of m/z 643 [M-H]-, corresponding to the expected
molecular mass of 644 for novclobiocin 401. MS/MS analysis
(Figure 4C) showed a fragmentation pattern corresponding to
that identified in previous mass spectrometric studies of amino-
coumarin antibiotics (Kammerer et al., 2004). High resolution
ESI-MS in positive mode showed a molecular ion of m/z =
645.14858, which is in agreement with the calculated value of
m/z = 645.14818 (C30H30N2O12Cl [M+H]
+; D 0.62 ppm).
Unidimensional (1H NMR, 13C NMR) and multidimensional
(1H-1H COSY, 1H HSQC, and 1H HMBC) NMR spectroscopy
confirmed the expected structure. Chemical shifts for the
substituted pyrrole, the deoxysugar and the aminocoumarin
moiety were in accordance to those of clorobiocin (Eusta´quio
et al., 2003). The chemical shifts and coupling patterns of the
protons in 1H NMR spectra of novclobiocin 401 showed the
catechol structure of the new acyl moiety. A strong high-field
13C NMR shift for carbon C-2 (dC = 116.1) and C-4 (dC =
150.8) in novclobiocin 401 compared to clorobiocin (dC-2 =
130.9, dC-4 = 161.0) indicated a new hydroxyl substitution in
ortho-position (C-3). Additionally, the NMR spectra of novclo-
biocin 401 lack all proton and carbon NMR signals of the dime-
thylallyl group of the native clorobiocin. Full comparative 1H
and 13C NMR spectroscopic data of novclobiocin 401 and clor-
obiocin as well as 1H-1H COSY, 1H HSQC and 1H HMBC corre-
lations from 2D NMR experiments for novclobiocin 401 are
given in Table S1, Figures S2 and S3, and Supplemental Exper-
imental Procedures.gyrase and topoisomerase IV. The first lane labeled with C contains control
assays without enzyme. The lane labeled 0 contains assays with addition of
3 ml solvent (5% aqueous DMSO). The following lanes contain assays to which
the indicated amount of antibiotic, dissolved in 5%DMSO, has been added. In
the supercoiling assays, the lower band shows supercoiled pBR322 DNA,
formed under catalysis of DNA gyrase. In the decatenation assays, the lower
band shows decatenated kinetoplast DNA, formed under catalysis of topoiso-
merase IV.Inhibitory activities against E. coli and S. aureus
DNA Gyrase and Topoisomerase IV
The new compound was investigated in vitro for its inhibitory
effects on E. coli and S. aureus DNA gyrase and topoisomerase
IV in comparison with the natural antibiotics clorobiocin and
novobiocin. Two different assays were used: a DNA gyrase
supercoiling assay and a topoisomerase IV decatenation assay.
The 50% inhibitory concentrations (IC50s) of novclobiocin 401
were determined as 0.006 mM for S. aureus DNA gyrase and
0.03 mM for E. coli DNA gyrase (Figure 5). These inhibitory
concentrations are identical to those observed with clorobiocin
and lower than those observed with the clinically used novobi-
ocin (inhibitory concentration: 0.01 mM and 0.08 against the
two gyrases, respectively). This clearly proves that the replace-
ment of the genuine Ring A moiety with a 3,4-DHBA moiety
had not affected the potency of the compound as gyrase
inhibitor.
DNA gyrase inhibitors of the fluoroquinolone class also inhibit
topoisomerase IV which is very similar to gyrase (Maxwell and
Lawson, 2003). Thus, we examined whether novclobiocin 401
also inhibits the decatenation activity of E. coli and S. aureus
topoisomerase IV. However, just as novobiocin and clorobiocin
the new compound inhibited topoisomerase IV from S. aureus
and E. coli only at much higher concentrations than required
for gyrase inhibition (IC50 values: 35 mM for S. aureus topoiso-
merase IV and >50 mM for E. coli topoisomerase IV) (Figure 5).
Therefore, novclobiocin 401 is expected to act primarily as
gyrase inhibitor in both S. aureus and E. coli.308 Chemistry & Biology 18, 304–313, March 25, 2011 ª2011 ElsevieConstruction of E. coli Mutants for Investigation of
Antibiotic Import by Catechol Siderophore Transporters
As reported above, E. coli gyrase is equally sensitive to clorobio-
cin and novclobiocin 401. A difference in the antibacterial activity
of these two compounds may therefore be primarily caused by
either increased influx or decreased efflux. In order to observe
differences in influx without interferences by differences in efflux,
we inactivated the gene tolCwhich codes for an essential part of
the AcrAB/TolC and AcrAD/TolC drug efflux pumps of E. coli
(Blair and Piddock, 2009).
E. colipossesses three outermembrane transporters for active
import of catechol siderophores, i.e., Fiu, Cir, and FepA (Braun
and Hantke, 2001). All three transporters receive the energy for
active transport from the periplasmic binding protein TonB.
Expression of these proteins is upregulated under conditions of
iron starvation. Bacterial growth during an infection in the human
body represents a condition of extreme iron starvation (Chu et al.,
2010). For functional studies of catechol siderophore transport in
E. coli, conditions of iron starvation are usually created by (1)
mutation of entC which abolishes the biosynthesis of the impor-
tant siderophore enterobactin (Crosa and Walsh, 2002); (2)r Ltd All rights reserved
clorobiocin
novclobiocin 
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novobiocin
E. coli (ΔtolC/ΔentC) E. coli (ΔtonB/ΔtolC/ΔentC)
Figure 6. Determination of the Antibacterial
Activity by Disk Diffusion Assays
The antibacterial activity of clorobiocin, novo-
biocin, and novclobiocin 401 was determined
against E. coli mutants with and without active
TonB. To improve visualization of the inhibition
zones, living cells were stained with 2,3,5-tri-
phenyltetrazolium chloride.
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Artificial Pathway to a New Coumarin Antibioticaddition of the iron chelator 2,20-bipyridyl to the culture medium
(Alves et al., 2010; Mo¨llmann et al., 2009). We therefore decided
to use DentCmutants and 2,20-bipyridyl containing media.
The involvement of the catechol siderophore transporters Fiu,
Cir, and FepA in the uptake of novclobiocin 401 can be investi-
gated by comparing mutants with and without active TonB for
their sensitivity to clorobiocin and novclobiocin 401. As
described above, TonB energizes all three catechol transporters.
Due to these considerations, we decided to generate an E. coli
DtolC/DentC mutant as well as an E. coli DtonB/DtolC/DentC
mutant and to compare their sensitivity to clorobiocin and nov-
clobiocin 401. Single gene in-frame deletion mutants of entC,
tolC, and tonB in E. coliK-12 were available from the Keio collec-
tion (Baba et al., 2006). Using these strains, we generated E. coli
DtolC/DentC and E. coli DtonB/DentC double mutants as well as
an E. coli DtonB/DtolC/DentC triple mutant by Red/ET-mediated
recombination (see Experimental Procedures). The correct
genotype of the mutants was verified by PCR analysis of the
genomic DNA of the mutant.
Antibacterial Activity of Novclobiocin 401
The antibacterial activity of novclobiocin 401, in comparison to
clorobiocin and novobiocin, was first tested in disk diffusion
assays with the E. coli DtolC/DentC and the E. coli DtonB/
DtolC/DentC mutants. To improve visualization of the inhibition
zones, living cells on the agar plates were stained with 2,3,5-tri-
phenyltetrazolium chloride. The results are shown in Figure 6.
Against the mutant with intact TonB, novclobiocin 401 shows
approximately 2-fold higher activity than clorobiocin, and
4-fold higher activity than novobiocin. In contrast, against the
E. coli mutant with deleted tonB novclobiocin 401 is approxi-
mately 10-fold less active than clorobiocin. This shows that
TonB-dependent transport plays an important role in the anti-
bacterial activity of novclobiocin 401 but not in the activity of
clorobiocin and novobiocin.
We also determined the minimal inhibitory concentrations in
a liquid culture, following the procedure described by Wiegand
et al. (2008), but including 50 mM 2,20-bipyridyl into the culture
media. Under these conditions, theminimal inhibitory concentra-
tions of novobiocin and clorobiocin against E. coli DtolC/DentC
double mutants were 23 and 12 mg/ml, respectively. The
MIC of novclobiocin 401was 6 mg/ml, showing again that novclo-
biocin 401 had a higher antibacterial activity than its parent
compound clorobiocin against this mutant. Against theChemistry & Biology 18, 304–313, March 25, 2011DtonB/DtolC/DentC triple mutant, novo-
biocin and clorobiocin gave the same
MIC values as observed against the
DtolC/DentC double mutant (23 and
12 mg/ml, respectively). However, novclo-biocin 401 showed much less activity against the tonB-deficient
triple mutant (MIC: 47 mg/ml) than against the doublemutant with
active tonB (MIC: 6 mg/ml). This shows again that TonB-depen-
dent transport is important for the antibacterial activity of novclo-
biocin 401, but not of novclobiocin and clorobiocin.
Against the wild-type strain E. coli K-12, the MICs of novobi-
ocin, clorobiocin and novclobiocin 401 resulted as 375, 47,
and 95 mg/ml. Therefore, against the wild-type novclobiocin
401 was less active than its parent compound clorobiocin (see
Discussion). The poor activity of aminocoumarins against wild-
type strains ofE. coli is in accordancewith previous observations
(Anderle et al., 2008; Galm et al., 2004b).
DISCUSSION
The present study provides an example for the rational design of
a structurallymodifiedantibioticbyutilizing syntheticbiologyprin-
ciples.Our engineeringstrategy involvedgenes from fourdifferent
organisms: (1) the Gram-negative organism E. coli as the source
of ubiC, which codes for an enzyme of an anabolic pathway; (2)
the Gram-positive organism Corynebactericum cyclohexanicum
as the source of pobA, coding for an enzyme of a catabolic
pathway; (3) Streptomyces roseochromogenes as the source of
the biosynthetic gene cluster of clorobiocin, which was modified
by deletion of cloQ; (4) Streptomyces coelicolorM512 as heterol-
ogous expression host. S. coelicolor M512 (Floriano and Bibb,
1996) is a derivative of the strain S. coelicolor A3(2). Strain M512
does not produce three of the genuine antibiotics of strain A3(2),
i.e., methylenomycin, actinorhodin, and undecylprodigiosine,
which facilitates the detection and isolation of heterologously
produced compounds. The modified clorobiocin gene cluster
was stably integrated into the chromosome of this organism,
and the synthetic operon containing ubiC andpobA under control
of the strong constitutive ermE* promoter was expressed from
a replicative plasmid. This readily resulted in the production of
the desired compound novclobiocin 401. The yield of novclobio-
cin 401 exceeded that of clorobiocin reported for both the wild-
type and for a heterologous producer strain (Eusta´quio et al.,
2005). Even without extensive optimization experiments, novclo-
biocin 401 represented a major compound in the culture extract
(Figure 4A) which facilitated the preparative isolation of the
compound. Recently, improved heterologous expression strains
have been derived from S. coelicolor and may offer a benefit in
future experiments (Gomez-Escribano and Bibb, 2010).ª2011 Elsevier Ltd All rights reserved 309
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impairment of growth of the heterologous producer strain.
Apparently, both the diversion of chorismate for the production
of 3,4-DHBA and the accumulation of the potent gyrase inhibitor
novclobiocin 401 were tolerated well. Self-resistance of the
heterologous producer strain was expected, as the clorobiocin
gene cluster, expressed in S. coelicolor M512, contains an
aminocoumarin resistance gene (Eusta´quio et al., 2005).
The genetic engineering experiment resulted in a clorobiocin
derivative in which the genuine Ring A (Figure 1) is replaced
with a 3,4-DHBA moiety. In vitro investigation of the inhibitory
effect of this compound on the gyrases of E. coli and S. aureus
showed no change of activity in comparison to the parent
compound clorobiocin. This confirms that the structure of
Ring A is of little importance for the interaction of aminocoumarin
antibiotics with their principal target, and can be modified to
introduce desirable motifs into the molecule. It should be noted
that the IC50 of novclobiocin 401 against the gyrases of E. coli
and Staphylococcus aureus is two to three orders of magnitude
lower than that of modern fluoroquinolones (Takei et al., 2001),
confirming the strong potency of aminocoumarins.
Novclobiocin 401, containing a catechol motif, showed higher
antibacterial activity than its parent compound clorobiocin
against E. colimutants whichwere defective in their TolC-depen-
dent efflux pumps. When additionally tonB was deleted, the
activity of novclobiocin 401 was reduced eightfold (as calculated
from the MIC values), while the activity of clorobiocin remained
unchanged. TonB supplies the energy for the catechol sidero-
phore transporters Cir, Fiu, and FepA, and therefore this result
strongly suggests that these transporters are involved in the
active import of novclobiocin 401. Previous experiments showed
that especially Cir and Fiu have a broad substrate specificity and
can import catechol compounds with quite different structures
(Heinisch et al., 2003).
Uptake of drug-siderophore conjugates by Cir and Fiu has
been demonstrated previously, especially for cephalosporin-
catechol conjugates (Heinisch et al., 2003; Mo¨llmann et al.,
2009). In these experiments, the catechol moiety conjugated to
the antibiotic added considerably to the molecular weight of
the drug; often the size of the catechol moiety exceeded the
size of the antibiotic moiety. In the present study, a preexisting
moiety (i.e., Ring A) of the antibiotic was replaced by a catechol
moiety, and themolecular weight of the new catechol compound
(645 Da) was lower than that of the parent compound clorobiocin
(697 Da).
Though novclobiocin 401 was transported into E. coli cells
under involvement of TonB-dependent transporters, it did not
show higher activity than clorobiocin against wild-type and
DentCmutants of E. coli. The MIC values of clorobiocin and nov-
clobiocin 401 against DentC mutants were 23 and 95 mg/ml,
respectively. Under identical conditions, the MICs against
DentC/DtolC double mutants were 12 and 6 mg/ml, respectively.
These results suggest that novclobiocin 401 is more rapidly ex-
ported than clorobiocin by TolC-dependent drug efflux pumps.
The introduction of a catechol moiety into the clorobiocin mole-
cule therefore had the desired effect to facilitate active import by
catechol siderophore transporters, but also the undesired effect
to accelerate TolC-dependent efflux. Future attempts to improve
the activity of aminocoumarins against Gram-negative organism310 Chemistry & Biology 18, 304–313, March 25, 2011 ª2011 Elseviemay therefore aim at a reduced efflux, either by modification of
the drug or by combination with an efflux pump inhibitor, and
at a further improvement of active import, e.g., by inclusion of
a 2,3-DHBA moiety which is the catechol moiety present in en-
terobactin. The chemical synthesis of a clorobiocin derivative
with a 2,3-DHBA moiety is not straightforward, since a clorobio-
cin derivative lacking Ring A (e.g., containing only Rings B and C,
Figure 1) can not be obtained from any producer strain, due to
the fact that Ring A is the starter moiety for clorobiocin biosyn-
thesis. The de novo chemical synthesis of an entire aminocou-
marin antibiotic is a complicated multistep procedure (Laurin
et al., 1999). Generation of a clorobiocin derivative with a 2,3-
DHBA moiety by genetic engineering depends on the identifica-
tion of an aminocoumarin acyl ligase which, in contrast to the
presently known enzymes, can accept 2,3-DHBA as substrate
(Figure 2). A search for such an aminocoumarin acyl ligase is
currently under way in our laboratory.
SIGNIFICANCE
The present study provides an example that the rational
modification of the structure of an antibiotic can be achieved
by a synthetic biology approach. Specifically, we planned to
replace a structural moiety which was not required for anti-
biotic activity by a different moiety which would serve as an
‘‘import handle,’’ facilitating the import of the antibiotic into
the bacterial cell by catechol siderophore transporters. Our
study provides a proof-of-principle for this strategy. It
confirms earlier results that catechol siderophore trans-
porters can be used in a ‘‘Trojan horse’’ approach for the
active import of an antibiotic. We achieved the incorporation
of a catecholmotif into the structure of the antibiotic utilizing
a synthetic biology strategy. Such strategies are promising
for the generation of new bioactive molecules in future.
The growing number of sequenced biosynthetic gene clus-
ters andmicrobial genomesprovides a rich pool for enzymes
which can be reassembled to generate artificial biosynthetic
pathways. In the present study, genes from three different
organisms were combined in a fourth organism, resulting
in the biosynthesis of the desired antibiotic. DNA synthesis
was used to adapt the codon usage of two of the introduced
genes to the requirement of the expression host. We used
a genetically engineered and fully sequenced expression
host which is amenable to rapid genetic manipulation
and devoid of several interfering biosynthetic pathways.
Considering the current advances in the technologies for
DNA sequencing, DNA synthesis, DNA manipulation, and
engineering of expression hosts, many new bioactive
compounds may be accessible in future by the generation
of artificial biosynthetic pathways. The present study
provides an example for such an approach.
EXPERIMENTAL PROCEDURES
Chemicals
Novobiocic acid was isolated from Streptomyces spheroides AM1T2 (Steffen-
sky et al., 2000b); 3-amino-4,7-dihydroxy-8-methyl-coumarin (Ring B) was
kindly provided by Pharmacia & Upjohn, Inc. (Kalamazoo, MI). 3-Dimethyl-
allyl-4-hydroxybenzoic acid (Ring A) was obtained by hydrolysis of novobiocin
(Kominek and Meyer, 1975). Novobiocin and catechol compounds werer Ltd All rights reserved
Chemistry & Biology
Artificial Pathway to a New Coumarin Antibioticpurchased fromSigma-Aldrich. Clorobiocin was kindly provided by A.Maxwell
(John Innes Centre, Norwich, UK).
Bacterial Strains, Plasmids, Cosmids, and Culture Conditions
The E. coli andStreptomyces strains, plasmids, and cosmids used in this study
are listed in Table S2. E. coli strains were cultivated in liquid or on solid LB
medium at 37C. Streptomyces strains were routinely precultivated in liquid
TSBmedium (BDBioscience) at 30C for 2 days. The cultivationwas continued
in distillers’ solubles medium (Mancy et al., 1974), GYM medium (Shima et al.,
1996), and CDMmedium (Kominek, 1972) for antibiotic production at 30C for
5–8 days. Standard methods for cultivation, DNA isolation and manipulation
were performed as described by Sambrook and Russell, (2001) and Kieser
et al. (2000).
Assay for Aminocoumarin Acyl Ligase
The assay contained 2mMof the respective acyl substrate (3,4-dihydroxyben-
zoic acid, 2,3-dihydroxybenzoic acid, caffeic acid, 3,4-dihydroxyphenylacetic
acid, 3,4-dihydroxypropionic acid or 3,4-dihydroxymandelic acid), 2 mM 3-
amino-4,7-dihydroxy-8-methyl-coumarin (Ring B), 5 mM ATP, 5 mM MgCl2,
10 mM ascorbic acid, 100 mm Tris-HCl (pH 8.0) and 10 mg of the respective
enzyme in a final volume of 100 ml. The reaction was carried out for 45 min
at 30C and stopped by addition of 5 ml 1.5 M trichloroacetic acid. The reaction
mixture was extracted with 100 ml ethyl acetate. The organic layer was used for
analysis. After evaporation of the solvent and dissolution in methanol, the
sample was analyzed by HPLC with a Multosphere RP18-5 column (250 3
4 mm, 5 mm; Agilent) at a flow rate of 1 ml$min-1. A linear gradient from 60%
to 100% solvent B (solvent A H2O/HCOOH 99:1; solvent B MeOH/HCOOH
99:1) over 30 min was used. UV detection was carried out at 330 nm. Novobio-
cic acid was used as standard.
Inactivation of cloQ in Cosmid clo-BG1 andHeterologousExpression
In cosmid clo-BG1 (Eusta´quio et al., 2005) cloQ was replaced by Red/ET-
mediated recombination with an apramycin-resistance (aac(3)IV) cassette
that was flanked by XbaI and SpeI recognition sites. For replacement of
cloQ, the cassette was generated by PCR using pUG019 (Eusta´quio et al.,
2005) as template and the primers cloQ_f (50-GGC GCG CCC ATT GCT CAC
CGT CTT ACC GAC ACC GTC CTT ATT CCG GGG ATC TCT AGA TC-30)
and cloQ_r (50-TCC CAT GGT CGA TTC CGT GTG TTG GTG AAG TGC GCG
CAG ACT AGT CTG GAG CTG CTT C-30). Underlined letters indicate the
XbaI and SpeI restriction sites. PCR amplification was performed in 50 ml
volume with 100 ng template, 0.25 mM dNTPs, 50 pmol of each primer, and
5% (v/v) DMSO with the Expand High Fidelity PCR system (Roche Molecular
Biochemicals): denaturation at 94C for 2 min, then 10 cycles with denatur-
ation at 94C for 45 s, annealing at 50C for 45 s, and elongation at 72C for
90 s, followed by 15 cycles with annealing at 55C for 45 s, and the last elon-
gation step at 72C for 5 min. The PCR product was introduced by electropo-
ration into E. coli BW25113/pIJ790 harboring cosmid clo-BG1 (Eusta´quio
et al., 2005). The resulting modified cosmid was isolated, transformed into
the nonmethylating strain E. coli ET12567, reisolated, and digested with
XbaI and SpeI to remove the apramycin-resistance cassette. Religation over-
night at 4C gave the cosmid clo-SA2.
The cosmid clo-SA2 isolated from E. coli ET12567 was introduced into
S. coelicolor M512 by PEG-mediated protoplast transformation (Kieser
et al., 2000). Clones resistant to kanamycin were selected. Feeding experi-
ments were carried out by addition of 1 mg Ring A (3-dimethylallyl-4-hydrox-
ybenzoic acid) dissolved in 100 ml ethanol to 80ml S. coelicolorM512(clo-SA2)
culture in distillers’ solubles medium (Eusta´quio et al., 2003).
For mutasynthesis experiments, 3 mg of the respective catechol
compounds were dissolved in 100 ml ethanol and added to 80 ml of the culture
of the cloQ-defective strain S. coelicolor M512(clo-SA2) in distillers’ solubles
medium one day after inoculation. After 5–8 days cultivation at 30C and
210 rpm, the cultures were extracted and analyzed by HPLC described below.
Design of the Synthetic Gene Operon
The nucleotide sequences of the genes pobA coding for a 4-hydroxybenzoate
hydroxylase from Corynebacterium cyclohexanicum (GenBank AB210281)
and ubiC coding for a chorismate pyruvate-lyase from Escherichia coli
536 (GenBank NC_008253) were redesigned using the codon preference ofChemistry & Biology 18, 3Streptomyces coelicolor (DNA2.0 Gene Designer Software). The two genes
were linked by translational coupling and flanked by SpeI and HindIII restriction
sites. The DNA fragment was commercially synthesized by DNA2.0 (Menlo
Park, CA) and provided in the vector pJ201. The nucleotide sequence of the
synthetic ubiC/pobA DNA fragment is shown in Figure S1.
Construction of the Plasmid pSA11
The synthetic ubiC/pobA fragment was isolated from the pJ201 vector
(DNA2.0) by restriction digest with SpeI and HindIII and cloned into
pUWL201 (Doumith et al., 2000) which contains the constitutive ermE*
promoter for foreign gene expression. Transformation of pSA11 into the inte-
gration mutant S. coelicolorM512(clo-SA2) was carried out by PEG-mediated
protoplast transformation (Kieser et al., 2000). Transformed colonies appeared
after 5 days at 30C.
Production and Purification of Novclobiocin 401
S. coelicolor M512(clo-SA2)/pSA11 was precultivated in TSB medium (BD
Bioscience) with 50 mg/ml thiostrepton for 3 days and then used to inoculate
40 flasks, each containing 50 ml CDM production medium (Kominek, 1972)
with 50 mg/ml thiostrepton. The cultivation was carried out for 5 days at
30C and 210 rpm. The culture was adjusted to pH 4 with hydrochloric acid
and extracted twice with an equal volume of ethyl acetate. The organic layer
was evaporated to dryness. The residue was dissolved in methanol and puri-
fied by HPLC with a Multosphere column 120 RP18-5 (250 3 20 mm, 5 mm;
C&S Chromatographie Service Du¨ren, Germany) at a flow rate of 2 ml/min. A
linear gradient from 70% to 100% solvent B in solvent A over 36 min was
used (solvent A H2O/HCOOH 99:1; solvent B MeOH: HCOOH 99:1).
For analytical purposes, 1 ml bacterial culture was acidified with HCl to pH 4
and extracted with equal volume of ethyl acetate. After evaporation of the
solvent, the residue was redissolved in 100 ml methanol. Eighty microliters
was analyzed by HPLC with a Multosphere RP18-5 column (250 3 4 mm,
5 mm; Agilent) at a flow rate of 1 ml/min. A linear gradient from 60% to 100%
solvent B over 23 min was used. UV detection was carried out at 280 nm.
DNA Gyrase and Topoisomerase IV Activity Assays
Relaxed pBR322 DNA and kDNA (from Crithidia fasciculata), DNA gyrase and
topoisomerase IV enzymes from E. coli and S. aureus were obtained from In-
spiralis (Norwich, UK). DNA gyrase and topoisomerase IV holoenzymes were
reconstituted by mixing approximately equimolar amounts of recombinant
E. coli and S. aureusGyrA and GyrB and ParC and ParE subunits, respectively.
DNA gyrase activity was measured by a supercoiling assay that monitored the
ATP-dependent conversion of relaxed pBR322 DNA to the supercoiled form.
Topoisomerase IV activity was measured by a decatenation assay that moni-
tored the ATP-dependent unlinking of DNA minicircles from kDNA. Details of
the assay procedures are described in the Supplemental Experimental
Procedures.
Agar Diffusion Tests
Agar plates (40 ml medium) were prepared by suspending 1 ml of a culture of
the respective E. coli mutant (overnight culture in LB medium, OD600 1.2) and
50 mM 2,20-bipyridyl in melted Mueller-Hinton agar (Roth). To paper disks of
7 mm diameter, different amounts of the respective antibiotic, dissolved in
15 ml methanol, were applied. These disks were placed on the agar plates
which were incubated at 37C for 16 hr. For visualization of living cells, 5 ml
of 0.5% aqueous 2,3,5-triphenyltetrazolium chloride (Roth) were added to
the plates, and after further incubation for 10 min, the inhibition zones were
determined.
Generation of E. coli Mutants
E. coli double and triple mutants were generated from E. coli K-12 MG1655
mutants obtained from the Keio collection (Baba et al., 2006). The gene entC
was replaced in E. coli JW5195-1/pIJ790 and JW5503-1/pIJ790 using Red/
ET-mediated recombination (Gust et al., 2003). An apramycin resistance
cassette [acc(3)IV] was amplified from plasmid pIJ773 (Gust et al., 2003).
The primers used for PCR were as follows: entC_f: (50-TCA TTA TTA AAG
CCT TTA TCA TTT TGT GGA GGA TGA TAT GAT TCC GGG GAT CCG TCG
ACC-30) and entC_r (50-CCG GCC AGC GGG TGA ATG GAA TGC TCA TCC
TCG CTC CTT ATG TAG GCT GGA GCT GCT TC-30). Italic letters represent04–313, March 25, 2011 ª2011 Elsevier Ltd All rights reserved 311
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The gene tolC was replaced in E. coli JW5195-1/pIJ790 using Red/ET-medi-
ated recombination (Gust et al., 2003). For this purpose, a streptomycin resis-
tance cassette [aadA] was amplified from plasmid pIJ778 (Gust et al., 2003)
using the primer pair tolC_f (50-GAT CGC GCT AAA TAC TGC TTC ACC
ACA AGG AAT GCA AAT GAT TCC GGG GAT CCG TCG ACC-30) and tolC_r
(50-ACG TTC AGA CGG GGC CGA AGC CCC GTC GTC GTC ATC ATG TAG
GCT GGA GCT GCT TC-30). The genotype of the resulting mutants was
confirmed by PCR with chromosomal DNA.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and two tables and can be found with this article online at
doi:10.1016/j.chembiol.2010.12.016.
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